Overview

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Status:
RECRUITING

Trial end date:
2032-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Phase:

PHASE3

Details

Lead Sponsor:

Taiho Oncology, Inc.

Treatments:

Carboplatin
Cisplatin
Pemetrexed
zipalertinib